Imprimis NJOF, LLC recalls Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthalmic Solution, 1% 0.5% 2.5% 0.5%, 5 mL fill in 15 mL bottle, Imprimis…
Sub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-110.0% of the label claim.
Read the official notice →- Date
- 2025-04-09
- Country
- United States
- Brand
- Imprimis NJOF
- Product
- Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthalmic Solution, 1% 0.5% 2.5% 0.5%, 5 mL fill in 15 mL bottle, Imprimis…
- Classification
- Class III
- Units
- FL and NY
- Category
- Drugs & medical
- Source
- FDA · Drug
Copied automatically from the US Food and Drug Administration. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer
What to do
- Check the product name, strength and lot number against the official notice.
- Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
- Ask the pharmacy or supplier about a replacement or refund.
General guidance from Recall Atlas. The official notice from the US Food and Drug Administration has the exact models, batch codes and remedy, and it takes priority.
More Imprimis NJOF recalls
- 2026-01-14
USImprimis NJOF, LLC recalls Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46…
Presence of particulate matter - Glass like particles.
- 2025-11-26
- US
- 2025-07-30
- US
Imprimis NJOF, LLC recalls Tropicamide-Proparacaine-Phenylephrine-Ketorolac, Sterile Ophthalmic Solution, 1% 0.5% 2.5% 0.5%, 5mL, 2x5ML vial per carton, Rx Only,…
Sub-Potent Drug: Subpotent assay results during stability testing.
- 2024-06-19
- US
- 2024-06-05
- US
- 2024-05-08
- US
Other drugs & medical recalls in the United States
- 2025-04-09
- US
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical…
CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
- US
Amerisource Health Services LLC recalls Voriconazole Tablets, 50 mg, packaged in cartons of 3 blister cards with 10 individual blistered doses (30 Unit Dose per…
cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.
- US
BIOCON PHARMA INC recalls Atorvastatin Calcium Tablets USP 40 mg, 1000-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ 08830-3009 USA,…
Failed dissolution specifications: lower than specifications
- US
The Harvard Drug Group LLC dba Major Pharmaceuticals and… recalls Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only,…
Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.
FDA · DrugThe Harvard Drug Group LLC dba Major Pharmaceuticals and…Nationwide in the USAOfficial notice → - 2025-04-02
- US
Baxter Healthcare Corporation recalls Progressa Bed Surfaces, intended to be used to treat or prevent pulmonary or other complications associated with immobility,…
The air bladders inside the mattress may move out of position when the head of the bed is elevated, causing a dip in the mattress.
- US
Checkpoint Surgical Inc recalls Brand Name: Checkpoint Guardian Intraoperative Lead Product Name: Checkpoint Guardian Intraoperative Lead, Small Model/Catalog Number:…
Adhesive on the back of the lead may not fully encapsulate the metallic portion of the wire and button subassembly, potentially leading to exposed metal. There is a risk of electrical current leakage, which may lead to…